Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 5/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | CASP3 | P42574 | 1/20 | 0.31 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.31 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.31 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | ALK | Q9UM73 | 4/20 | 0.30 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.30 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.30 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13487730 | 0.97 | ALK (0.31) | PDK2ALK | |
| SCHEMBL13487883 | 0.97 | PDK2 (0.35) | PDK2PLA2G10PLA2G2APLA2G4A | |
| SCHEMBL24285577 | 0.95 | L3MBTL1 (0.33) | PDK2L3MBTL1ALOX5CA1CA2 | |
| SCHEMBL13488037 | 0.94 | CASP3 (0.32) | L3MBTL1CASP3SENP7SENP6HCRTR1 | |
| SCHEMBL13487342 | 0.93 | PDK2 (0.31) | PDK2ALOX5 | |
| SCHEMBL17944077 | 0.93 | ALK (0.33) | PDK2L3MBTL1ALOX5CA1CA2 | |
| SCHEMBL13487963 | 0.93 | ENPP3 (0.33) | L3MBTL1ALOX5 | |
| SCHEMBL13487803 | 0.92 | MAOB (0.35) | PDK2L3MBTL1ALK | |
| SCHEMBL13488218 | 0.92 | MAOB (0.35) | PDK2L3MBTL1ALK | |
| SCHEMBL26404244 | 0.91 | PLA2G2A (0.37) | PDK2L3MBTL1CASP3SENP7SENP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100045170-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2010-02-25 | — | — | US | disclosed |
| US-20100045170-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100045170-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | OCIAD1, OCIAD2, ORMDL3 | PDK2 1456/4885L3MBTL1 1193/4885ALOX5 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.